Published in Drug Saf on December 01, 2013
'Trust but verify' - five approaches to ensure safe medical apps. BMC Med (2015) 1.20
Computational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworks. Drug Saf (2015) 0.79
Increasing Patient Engagement in Pharmacovigilance Through Online Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reporting for the Essure Device in the US. Pharmaceut Med (2015) 0.79
Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials. JAMA Oncol (2016) 0.77
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. Prog Retin Eye Res (2016) 0.77
The logic of surveillance guidelines: an analysis of vaccine adverse event reports from an ontological perspective. PLoS One (2014) 0.77
Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan. Springerplus (2016) 0.75
Patient Participation and the Use of Ehealth Tools for Pharmacoviligance. Front Pharmacol (2016) 0.75
The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization. Drug Saf (2016) 0.75
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials (1989) 15.99
Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet (2010) 12.92
Under-reporting of adverse drug reactions : a systematic review. Drug Saf (2006) 6.69
Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA (2002) 5.30
Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA (2013) 4.98
Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med (2010) 4.32
The missing voice of patients in drug-safety reporting. N Engl J Med (2010) 4.23
A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol (1998) 3.88
Emerging patient-driven health care models: an examination of health social networks, consumer personalized medicine and quantified self-tracking. Int J Environ Res Public Health (2009) 3.46
Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med (2012) 3.26
Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet (2005) 3.18
Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care (2008) 3.08
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol (2004) 2.92
Patient-reported medication symptoms in primary care. Arch Intern Med (2005) 2.89
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess (2011) 2.71
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56
Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf (2010) 2.29
Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc (2013) 2.19
Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf (2012) 1.79
Safety surveillance of longitudinal databases: methodological considerations. Pharmacoepidemiol Drug Saf (2011) 1.48
Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ (2001) 1.43
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
Predicting adverse drug events from personal health messages. AMIA Annu Symp Proc (2011) 1.40
Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ (1996) 1.22
Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst (2011) 1.21
Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study. Drug Saf (2013) 1.04
Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer (2010) 0.98
Web-based patient-reported outcomes in drug safety and risk management: challenges and opportunities? Drug Saf (2012) 0.95
Managing adverse drug reactions: an orphan task. J Adv Nurs (2002) 0.94
Monitoring adverse drug reactions: scales, profiles, and checklists. Int Nurs Rev (2004) 0.94
Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf (2004) 0.93
Integration of clinical and patient-reported outcomes in surgical oncology. Br J Surg (2012) 0.91
How do doctors refer to patient-reported outcome measures (PROMS) in oncology consultations? Qual Life Res (2012) 0.90
NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist (2009) 0.89
Use of triage strategies in the WHO signal-detection process. Drug Saf (2007) 0.89
Patient-reported outcomes in drug safety evaluation. Ann Oncol (2009) 0.88
Systematic collection of patient-reported adverse drug reactions: a path to patient-centred pharmacovigilance. Drug Saf (2013) 0.82
Development and clinical gains of nurse-led medication monitoring profiles. J Nurs Manag (2013) 0.79
Patient-reported outcome in colorectal health and disease. Colorectal Dis (2012) 0.77
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain (2003) 4.24
Sharing health data for better outcomes on PatientsLikeMe. J Med Internet Res (2010) 3.87
Against diagnosis. Ann Intern Med (2008) 3.69
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov (2008) 3.35
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn (2008) 2.71
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol (2009) 2.64
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56
Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur J Clin Pharmacol (2009) 2.55
The power of social networking in medicine. Nat Biotechnol (2009) 2.37
Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (2007) 2.36
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain (2006) 2.23
Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe. J Med Internet Res (2011) 2.19
Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine (2007) 2.16
Impact of pain on self-rated health in the community-dwelling older adults. Pain (2002) 2.12
Therapeutic applications of fenugreek. Altern Med Rev (2003) 2.12
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol (2010) 2.06
Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin (2012) 1.94
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care (2012) 1.84
Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend (2005) 1.82
Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. Eur J Pain (2005) 1.80
Understanding the context of health for persons with multiple chronic conditions: moving from what is the matter to what matters. Ann Fam Med (2014) 1.73
A statistical methodology for drug-drug interaction surveillance. Stat Med (2008) 1.69
A data mining approach for signal detection and analysis. Drug Saf (2002) 1.65
A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med (2010) 1.64
Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov (2011) 1.58
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy. Eur Urol (2011) 1.50
Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med (2004) 1.49
Safety surveillance of longitudinal databases: methodological considerations. Pharmacoepidemiol Drug Saf (2011) 1.48
How the Social Web Supports patient experimentation with a new therapy: The demand for patient-controlled and patient-centered informatics. AMIA Annu Symp Proc (2008) 1.47
Reliability of adverse symptom event reporting by clinicians. Qual Life Res (2011) 1.45
Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early stage endometrial cancer. Ann Surg Oncol (2014) 1.45
Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One (2013) 1.45
Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther (2013) 1.43
Supporting clinical practice decisions with real-time patient-reported outcomes. J Clin Oncol (2011) 1.41
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain Med (2010) 1.40
A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J (2014) 1.40
Labelling and 'Dear Doctor' letters: are they noncommittal? Drug Saf (2002) 1.39
Targeted drugs for metastatic renal cell carcinoma. Lancet (2007) 1.36
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. J Clin Oncol (2013) 1.34
Signal selection and follow-up in pharmacovigilance. Drug Saf (2002) 1.32
Patients' responsibility to participate in decision making and research. JAMA (2013) 1.32
Cancer-related fatigue. J Natl Compr Canc Netw (2010) 1.26
Skeletal and hematological anomalies in HYAL2-deficient mice: a second type of mucopolysaccharidosis IX? FASEB J (2008) 1.25
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer (2010) 1.25
Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf (2007) 1.23
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res (2010) 1.22
Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst (2011) 1.21
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res (2013) 1.21
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer (2013) 1.21
Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health (2012) 1.15
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum. Drug Saf (2014) 1.14
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12
Adult cancer pain. J Natl Compr Canc Netw (2010) 1.11
Social media and networks in pharmacovigilance: boon or bane? Drug Saf (2011) 1.10
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2012) 1.10
St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics (2003) 1.10
Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer (2008) 1.09
Impact of stratification on adverse drug reaction surveillance. Drug Saf (2008) 1.08
Boswellia: an evidence-based systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother (2004) 1.07
Adaptation and validation of the Treatment Burden Questionnaire (TBQ) in English using an internet platform. BMC Med (2014) 1.06
Validation of the German version of the brief fatigue inventory. J Pain Symptom Manage (2003) 1.05
Self-efficacy for coping with cancer in a multiethnic sample of breast cancer patients: associations with barriers to pain management and distress. Clin J Pain (2010) 1.05
Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med (2006) 1.04
Earlier discovery of pregabalin's dependence potential might have been possible. Eur J Clin Pharmacol (2010) 1.04
Quantifying short-term dynamics of Parkinson's disease using self-reported symptom data from an Internet social network. J Med Internet Res (2013) 1.03
Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study. Cancer (2011) 1.02
Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf (2011) 1.02
Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial. Amyotroph Lateral Scler (2012) 1.01
Stakeholder engagement in patient-centered outcomes research: high-touch or high-tech? Expert Rev Pharmacoecon Outcomes Res (2014) 1.01
Hyal2 is a glycosylphosphatidylinositol-anchored, lipid raft-associated hyaluronidase. Biochem Biophys Res Commun (2011) 1.00
Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology (2004) 1.00
Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw (2015) 1.00
Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak (2010) 0.98
African heat. Drug Saf (2010) 0.97
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol (2009) 0.96
The challenge of effectively communicating patient safety information. Expert Opin Drug Saf (2006) 0.96
Mining online social network data for biomedical research: a comparison of clinicians' and patients' perceptions about amyotrophic lateral sclerosis treatments. J Med Internet Res (2012) 0.95
Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation. Drug Saf (2014) 0.95
The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol (2013) 0.94
Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Pain Symptom Manage (2010) 0.94
Studying cancer-related fatigue: report of the NCCN scientific research committee. J Natl Compr Canc Netw (2010) 0.93
Two novel functions of hyaluronidase-2 (Hyal2) are formation of the glycocalyx and control of CD44-ERM interactions. J Biol Chem (2009) 0.93
Content validity of self-report measurement instruments: an illustration from the development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory. Oncol Nurs Forum (2005) 0.93
The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer (2011) 0.92
The king's foot of patient-reported outcomes: current practices and new developments for the measurement of change. Qual Life Res (2011) 0.92
Evidence-based systematic review of dandelion (Taraxacum officinale) by natural standard research collaboration. J Herb Pharmacother (2005) 0.91
Synthesis and fragmentation of hyaluronan in renal ischaemia. Nephrol Dial Transplant (2012) 0.91
The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain. J Pain Symptom Manage (2006) 0.91
Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance. Eur J Clin Pharmacol (2014) 0.90
Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med (2005) 0.90